Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes

Vaccine

Volumn 27, Issue 50, 2009, Pages 7087-7095

  Walker, Leslie E ^a   Vang, Lo ^a   Shen, Xuefei ^a   Livingston, Brian D ^a   Post, Penny ^b   Sette, Alessandro ^c   Godin, C Steven ^d   Newman, Mark J ^a  

^a Pharmexa Inc   (United States)

^b Protein Sciences Corp   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d Bridge Laboratories   (United States)

Author keywords

Cytotoxic T lymphocyte; DNA vaccine; Epitope; Helper T lymphocyte; HIV; Recombinant protein

Indexed keywords

CD45 ANTIGEN; DNA VACCINE; EP 1043 VACCINE; EP HIV 1090 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SAFETY; GUINEA PIG; HELPER CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RABBIT;

AIDS VACCINES; ANIMALS; CELL LINE; EPITOPES, T-LYMPHOCYTE; GUINEA PIGS; HIV ANTIGENS; HIV INFECTIONS; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMIDS; RABBITS; RECOMBINANT PROTEINS; VACCINES, DNA;

EID: 70350574705     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.059     Document Type: Article

References (56)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 (1994) 6103-6110
2. Koup R.A., Safrit J.T., Cao Y., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
3. + cells in human immunodeficiency virus type I pathogenesis: Cytolytic and noncytolytic inhibition of viral replication. Adv Immunol 66 (1997) 273-311
4. Klein M.R., Van Baalen C.A., Holwerda A.M., et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181 (1995) 1365-1373
5. Rowland-Jones S., Dong T., Krausa P., et al. The role of cytotoxic T-cells in HIV infection. Dev Biol Stand 92 (1998) 209-214
6. Rowland-Jones S., Tan R.S., and McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol 65 (1997) 277-346
7. Migueles S.A., Laborico A.C., Shupert W.L., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 (2002) 1061-1068
8. Frahm N., Adams S., Kiepiela P., et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 79 (2005) 10218-10225
9. Frahm N., Kiepiela P., Adams S., et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7 (2006) 173-178
10. Zuniga R., Lucchetti A., Galvan P., et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80 (2006) 3122-3125
11. Betts M.R., Nason M.C., West S.M., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
12. Cao Y., Qin L., Zhang L., Safrit J., and Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332 (1995) 201-208
13. Pantaleo G., Menzo S., Vaccarezza M., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332 (1995) 209-216
14. Rinaldo C., Huang X.-L., Fan Z., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 69 (1995) 5838-5842
15. + lymphocyte activity. J Infect Dis 172 (1995) 329-339
16. Harrer E., Harrer T., Barbosa P., et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 173 (1996) 476-479
17. Ogg G.S., Jin X., Bonhoeffer S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
18. Rowland-Jones S. Long-term non-progression in HIV infection: clinico pathological issues. J Infect 38 (1999) 67-70
19. Kalams S.A., Buchbinder S.P., Rosenberg E.S., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73 (1999) 6715-6720
20. Kalams S.A., and Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188 (1998) 2199-2204
21. + cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 5 (1999) 518-525
22. + T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 12 (2000) 375-380
23. Rosenberg E.S., Billingsley J.M., Caliendo A.M., et al. Vigorous HIV-1-specific CD4+ Tcell respsonses associated with control of viremia. Science 278 (1997) 1447-1450
24. Boritz E., Palmer B.E., and Wilson C.C. Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 78 (2004) 12638-12646
25. Migueles S.A., and Connors M. The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection. Curr Infect Dis Rev 4 (2002) 461-467
26. Matloubian M., Concepcion R.J., and Ahmed R. Cd4(+) T-Cells Are Required to Sustain Cd8(+) Cytotoxic T-Cell Responses During Chronic Viral-Infection. J Virol 68 (1994) 8056-8063
27. Cardin R.D., Brooks J.W., Sarawar S.R., and Doherty P.C. Progressive loss of CD8(+) T cell-mediated control of a gamma-herpesvirus in the absence of CD4(+) T cells. J Exp Med 184 (1996) 863-871
28. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., Von Herrath M.G., and Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003) 852-856
29. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003) 337-339
30. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
31. Catanzaro A.T., Koup R.A., Roederer M., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 (2006) 1638-1649
32. Catanzaro A.T., Roederer M., Koup R.A., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25 (2007) 4085-4092
33. Tavel J.A., Martin J.E., Kelly G.G., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acq Immun Def Synd 44 (2007) 601-605
34. Wilson C.C., McKinney D., Anders M., et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 171 (2003) 5611-5623
35. Douek D.C., Brenchley J.M., Betts M.R., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 (2002) 95-98
36. Brenchley J.M., Ruff L.E., Casazza J.P., Koup R.A., Price D.A., and Douek D.C. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 80 (2006) 6801-6809
37. Wilson C.C., Newman M.J., Livingston B.D., et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15 (2008) 986-994
38. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23 (2005) 975-1028
39. Sidney J., Southwood S., Oseroff C., Del Guercio M.-F., Grey H.M., and Sette A. Measurement of MHC/peptide interactions by gel filtration. Curr Prot Immunol 18 (1998) 18.3.2-18.3.19
40. Sette A., Sidney J., del Guercio M.F., et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 31 (1994) 813-822
41. Wilson C.C., Palmer B., Southwood S., et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 75 (2001) 4195-4207
42. Altfeld M.A., Livingston B., Reshamwala N., et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol 75 (2001) 1301-1311
43. Livingston B., Crimi C., Newman M., et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168 (2002) 5499-5506
44. McPherson C.E. Development of a novel recombinant influenza vaccine in insect cells. Biologicals (2008)
45. Gorse G.J., Baden L.R., Wecker M., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26 (2008) 215-223
46. Nicolaou M., Chang P., and Newman M.J. Use of Poly-N-vinyl pyrrolidone) with noncondensed plasmid dna formulations for gene therapy and vaccines. In: Amiji M.M. (Ed). Polymeric gene delivery principles and applications (2005), CRC Press 329-344
47. Kensil C.R., Patel U., Lennick M., and Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146 (1991) 431-437
48. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 19 (2000) 618-622
49. Ishizaka S.T., and Hawkins L.D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 6 (2007) 773-784
50. Brandenburg K., Lindner B., Schromm A., et al. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur. J Biochem 267 (2000) 3370-3377
51. Wentworth P.A., Vitiello A., Sidney J., et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 26 (1996) 97-101
52. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow-cytometry. J Immunol Methods 171 (1994) 131-137
53. Livingston B., Crimi C., Newman M., et al. A rational strategy to design multiepitope immunognes based on multiple TH lymphocyte epitopes. J Immunol 168 (2002) 5499-5506
54. Dolin R., Graham B.S., Greenberg S.B., et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Int Med 114 (1991) 119-127
55. Birx D.L., Loomis-Price L.D., Aronson N., et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. J Infect Dis 181 (2000) 881-889
56. Dalakouras T., Smith B.J., Platis D., Cox M.M., and Labrou N.E. Development of recombinant protein-based influenza vaccine. Expression and affinity purification of H1N1 influenza virus neuraminidase. J Chromatogr 1136 (2006) 48-56